Last reviewed 2026-05-21 · How we verify

Cordalin (ETOFYLLINE)

Phase 2 active Small molecule ✓ Verified May 2026

Cordalin (generic name: ETOFYLLINE) is a etofylline drug. It is currently in Phase 2 development.

Etofylline works by binding to the adenosine receptor A2b, which affects the activity of adenosine.

Cordalin is a small molecule with synonyms including Clofibrate Etofylline, and it is classified as a modality of small molecule.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETOFYLLINE
Drug class	etofylline
Target	Adenosine receptor A2b
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Think of adenosine like a messenger in your body that helps regulate various functions, such as heart rate and blood pressure. Etofylline helps control how strongly this messenger is received by its receptors, which can have different effects depending on the situation.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cordalin CI brief — competitive landscape report
Cordalin updates RSS · CI watch RSS

Frequently asked questions about Cordalin

What is Cordalin?

Cordalin (ETOFYLLINE) is a etofylline drug.

How does Cordalin work?

Etofylline works by binding to the adenosine receptor A2b, which affects the activity of adenosine.

What is the generic name of Cordalin?

ETOFYLLINE is the generic (nonproprietary) name of Cordalin.

What drug class is Cordalin in?

Cordalin belongs to the etofylline class. See all etofylline drugs at /class/etofylline.

What development phase is Cordalin in?

Cordalin is in Phase 2.

What does Cordalin target?

Cordalin targets Adenosine receptor A2b and is a etofylline.

Drug class: All etofylline drugs
Target: All drugs targeting Adenosine receptor A2b
Therapeutic area: All drugs in Cardiovascular

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing